About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PAXIL CR Bioequivalence Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00749359

PAXIL CR Bioequivalence Study

This study is to determine if controlled release paroxetine tablets manufactured at two different sites behave similarly in healthy volunteers.

Lead sponsor: GlaxoSmithKline•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Key Inclusion:
•Healthy males or females between 18-65. Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-30 kg/m2. Willing to use acceptable forms of birth control throughout the study. Normal labs and ECG.
•Key Exclusion:
•Positive test for drugs or alcohol. Positive for Hepatitis or HIV. Any history of psychiatric disorder or suicidal behavior. Has taken another investigational product within 30 days of the start of this study. Has been exposed to more than 4 new chemical entities in the last 12 months. Females who are pregnant or nursing. Regular consumption of alcohol; \>14 drinks/week for men or \>7 drinks/week for women. Heavy smokers; greater than 20 cigarettes per day.

Related studies

RECRUITINGPhase 3

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689 · Major Depressive Disorder

RECRUITINGPhase 2

Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression

NCT07539805 · Major Depressive Disorder (MDD), Probiotic Intervention

RECRUITINGPhase 2

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression

NCT07645157 · Major Depressive Disorder (MDD), Probiotic Intervention

Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients

NCT07642882 · Fibromyalgia, Depression - Major Depressive Disorder, and more

RECRUITINGPhase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407 · Major Depressive Disorder

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 4, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment166

Start dateJul 2008

Last updatedAug 4, 2017

Condition

Depressive Disorder

Locations shown

GSK Investigational Site

Buffalo, New York

GSK Investigational Site

Tacoma, Washington

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 4, 2017Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions